News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
232,050 Results
Type
Article (5103)
Company Profile (24)
Press Release (226923)
Multimedia
Podcasts (2)
Webinars (4)
Section
Business (82255)
Career Advice (463)
Deals (15054)
Drug Delivery (8)
Drug Development (19077)
Employer Resources (30)
FDA (3682)
Job Trends (3909)
News (120191)
Policy (7512)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (294)
Accelerated approval (6)
Adcomms (4)
Allergies (14)
Alliances (14808)
ALS (38)
Alzheimer's disease (294)
Antibody-drug conjugate (ADC) (40)
Approvals (3782)
Artificial intelligence (80)
Autoimmune disease (27)
Automation (5)
Bankruptcy (97)
Best Places to Work (2865)
Biosimilars (32)
Biotechnology (23)
Bladder cancer (34)
Brain cancer (7)
Breast cancer (101)
Cancer (886)
Cardiovascular disease (61)
Career advice (395)
Career pathing (3)
CAR-T (64)
CDC (2)
Cell therapy (166)
Cervical cancer (5)
Clinical research (16684)
Collaboration (353)
Compensation (371)
Complete response letters (8)
COVID-19 (311)
CRISPR (13)
C-suite (338)
Cystic fibrosis (28)
Data (1326)
Denatured (1)
Depression (21)
Diabetes (78)
Diagnostics (2114)
Digital health (7)
Diversity (1)
Diversity, equity & inclusion (13)
Drug discovery (31)
Drug pricing (14)
Drug shortages (2)
Duchenne muscular dystrophy (35)
Earnings (42739)
Editorial (5)
Employer branding (6)
Employer resources (32)
Events (39148)
Executive appointments (424)
FDA (4421)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (340)
Gene editing (24)
Generative AI (5)
Gene therapy (106)
GLP-1 (144)
Government (422)
Guidances (197)
Healthcare (5046)
HIV (10)
Huntington's disease (5)
IgA nephropathy (11)
Immunology and inflammation (39)
Immuno-oncology (7)
Indications (16)
Infectious disease (337)
Inflammatory bowel disease (36)
Inflation Reduction Act (3)
Influenza (6)
Intellectual property (32)
Interviews (53)
IPO (7880)
IRA (3)
Job creations (1122)
Job search strategy (361)
JPM (4)
Kidney cancer (10)
Labor market (10)
Layoffs (107)
Leadership (5)
Legal (2337)
Liver cancer (21)
Longevity (2)
Lung cancer (92)
Lymphoma (70)
Machine learning (3)
Management (10)
Manufacturing (139)
MASH (50)
Medical device (3918)
Medtech (3928)
Mergers & acquisitions (7579)
Metabolic disorders (214)
Multiple sclerosis (18)
NASH (6)
Neurodegenerative disease (54)
Neuropsychiatric disorders (12)
Neuroscience (539)
NextGen: Class of 2026 (1674)
Non-profit (730)
Now hiring (5)
Obesity (84)
Opinion (32)
Ovarian cancer (26)
Pain (28)
Pancreatic cancer (38)
Parkinson's disease (50)
Partnered (6)
Patents (51)
Patient recruitment (96)
Peanut (6)
People (25222)
Pharmaceutical (7)
Pharmacy benefit managers (2)
Phase 1 (4994)
Phase 2 (7225)
Phase 3 (5789)
Pipeline (1964)
Policy (17)
Postmarket research (626)
Preclinical (1948)
Press Release (66)
Prostate cancer (57)
Psychedelics (3)
Radiopharmaceuticals (109)
Rare diseases (179)
Real estate (1886)
Recruiting (8)
Regulatory (5537)
Reports (17)
Research institute (308)
Resumes & cover letters (69)
Rett syndrome (19)
RNA editing (1)
RSV (2)
Schizophrenia (49)
Series A (53)
Series B (54)
Sickle cell disease (10)
Special edition (1)
Spinal muscular atrophy (33)
Sponsored (5)
Startups (1019)
Stomach cancer (1)
Supply chain (13)
Tariffs (7)
The Weekly (1)
Vaccines (80)
Venture capital (9)
Weight loss (29)
Women's health (6)
Date
Today (2)
Last 7 days (147)
Last 30 days (609)
Last 365 days (8910)
2026 (786)
2025 (9040)
2024 (11037)
2023 (13201)
2022 (18660)
2021 (19679)
2020 (18238)
2019 (13206)
2018 (10205)
2017 (10001)
2016 (9156)
2015 (12120)
2014 (9587)
2013 (7707)
2012 (8331)
2011 (8796)
2010 (8635)
Location
Africa (186)
Alabama (19)
Alaska (2)
Arizona (74)
Arkansas (1)
Asia (11782)
Australia (1690)
California (3541)
Canada (1138)
China (167)
Colorado (143)
Connecticut (162)
Delaware (70)
Europe (25486)
Florida (548)
Georgia (67)
Idaho (24)
Illinois (161)
India (14)
Indiana (105)
Iowa (9)
Japan (164)
Kansas (36)
Kentucky (17)
Louisiana (8)
Maine (51)
Maryland (352)
Massachusetts (2803)
Michigan (104)
Minnesota (201)
Mississippi (1)
Missouri (31)
Montana (17)
Nebraska (12)
Nevada (46)
New Hampshire (16)
New Jersey (1018)
New Mexico (5)
New York (814)
North Carolina (479)
North Dakota (4)
Northern California (1854)
Ohio (116)
Oklahoma (5)
Oregon (6)
Pennsylvania (597)
Puerto Rico (1)
Rhode Island (19)
South America (279)
South Carolina (17)
Southern California (1304)
Tennessee (62)
Texas (480)
United States (12336)
Utah (111)
Virginia (84)
Washington D.C. (17)
Washington State (297)
West Virginia (2)
Wisconsin (57)
Wyoming (1)
232,050 Results for "adolor corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Adolore BioTherapeutics Announces FDA Orphan Drug Designation for its Kv7-activating rdHSV-CA8* Therapy in the Treatment of Erythromelalgia
January 15, 2026
·
7 min read
Press Releases
Dr. Roy Levitt, Executive Chairman of Adolore BioTherapeutics, Presented at the Next Generation Gene Therapy Vectors Summit
August 13, 2025
·
4 min read
Press Releases
Adolore BioTherapeutics to Present at Festival of Biologics USA 2025
April 24, 2025
·
3 min read
BioMidwest
Adolore BioTherapeutics to Present at the Virtual Investor Pitch Conference
Adolore BioTherapeutics, a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, announced that it will present at the Virtual Investor Pitch Conference on June 17, 2024 at 10:00 AM ET.
June 10, 2024
·
1 min read
Adolore BioTherapeutics Outlines Strategy for its Next Generation, Disease-Modifying, Non-Opioid Analgesic Gene Therapies for the Treatment of Chronic Pain
Adolore BioTherapeutics (“Adolore” or the “Company”), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today outlined recent pipeline development progress and provided a business outlook.
May 21, 2024
·
7 min read
Adolore BioTherapeutics to Participate at the Virtual Investor Ask the CEO Conference
Adolore BioTherapeutics (“Adolore” or the “Company”), a company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced that Roelof Rongen, CEO of Adolore, will participate at the Virtual Investor Ask the CEO Conference on Wednesday, October 25, 2023 at 3:00 PM ET.
October 11, 2023
·
2 min read
Press Releases
Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
June 16, 2025
·
6 min read
Adolore BioTherapeutics to Present at the 5th Annual National Institutes of Health (NIH) HEAL Initiative Scientific Meeting
Adolore BioTherapeutics (“Adolore” or the “Company”) today announced that Roy C. Levitt, MD, the Company’s founder and Executive Chairman, Clinical Professor, University of Miami, and Principal Investigator of a NIH, NINDS, HEAL UH3 Award will present at the 5th Annual NIH HEAL Initiative Scientific Meeting being held February 7-8, 2024 in Bethesda, Maryland.
January 30, 2024
·
4 min read
Press Releases
Adolore BioTherapeutics to Present CA8* Neuromodulating Gene Therapy at the 2025 NANS Annual Meeting
February 4, 2025
·
4 min read
Adolore BioTherapeutics Announces Issuance of First U.S. Patent Covering CA8* Gene Therapies to Treat Chronic Pain
Adolore BioTherapeutics (“Adolore” or the “Company”), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced the U.S. Patent and Trademark Office (USPTO) has issued patent No. 11,911,450 covering its innovative CA8* (*Carbonic anhydrase-8-like analgesic peptides, CA8 variants) gene therapies, using a state-of-the-art replication-defective disease-free HSV vector (rdHSV-CA8*).
March 4, 2024
·
5 min read
1 of 23,205
Next